Abstract Details

Title Impact of Seizure Frequency Reduction on Health-Related Quality of Life Among Clinical Trial Subjects with Refractory Partial-Onset Seizures: A Pooled Analysis of Phase III Clinical Trials of Eslicarbazepine Acetate

Topic Epilepsy/Clinical Neurophysiology (EEG)

Presentation(s) (-)

Poster/Presentation
Number 180

Background

Objective

Design/Methods

Results

Conclusions

Authors/Disclosures
PRESENTER	No disclosure on file
Fulton Velez	No disclosure on file
Rui Sousa	No disclosure on file
	No disclosure on file
	No disclosure on file
David E. Blum, MD	Dr. Blum has received personal compensation for serving as an employee of Neurona Therapeutics. Dr. Blum has stock in Neurona Therapeutics.
Joyce A. Cramer (Yale University School of Medicine)	No disclosure on file
	No disclosure on file